About Rakesh Karmacharya, MD, PhD

Dr. Rakesh Karmacharya is an Assistant Professor in Psychiatry at Harvard Medical School and the Director of Stem Cell Research of the Center for Experimental Drugs and Diagnostics. He is also a Physician-Scientist in the Chemical Biology Program at the Broad Institute of Harvard and MIT, and the Medical Director of the Schizophrenia and Bipolar Disorder Research Clinic at McLean Hospital.

Dr. Karmacharya received an A.B. in Biochemistry from Harvard University, an M.S. in Molecular Biophysics from Yale University and an MD and a PhD in Biophysics from the Albert Einstein College of Medicine in New York. His graduate studies focused on theoretical studies of the quantum mechanics of proton tunneling in condensed phase. He completed an internship in Medicine at Massachusetts General Hospital (MGH), and a residency in psychiatry at MGH and McLean Hospital. He served as the Chief Resident of the Schizophrenia and Bipolar Disorder Program. After his residency, he undertook postdoctoral studies in chemical biology under the mentorship of Prof. Stuart L. Schreiber.  

Departments, Centers, & Programs:

Clinical Interests:




Psychiatry Associates-Inpatient Consult
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-5600

Psychiatry-Outpatient Services
15 Parkman Street
Boston, MA 02114-3117
Phone: 617-724-5600

Medical Education

  • MD, PhD, Albert Einstein College of Medicine
  • Residency, Massachusetts General Hospital

American Board Certifications

  • Psychiatry, American Board of Psychiatry and Neurology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


View my most recent research

Dr. Karmacharya and his team are applying chemical biology approaches to identify "disease signatures" for schizophrenia and bipolar disorder, using neuronal cells generated from induced pluripotent stem cells (iPSCs). The goal is to find reliable and robust cellular features that segregate with disease than can serve as disease signatures. The identification of disease signatures will enable screens of small molecule libraries to delineate molecular targets that modulate these disease signatures and identify new diagnostic and therapeutic leads for schizophrenia and bipolar disorder.